Current Illinois CancerCare Clinical Trials

Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors.

Study Number: EAY191 - S3

Study Summary:
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Status: Open

Study Coordinator(s)
  • Navigator Ashton, 309-243-3611 atodd@illinoiscancercare.com
  • Navigator Carrie, 309-243-3621 cgeoffroy@illinoiscancercare.com
  • Navigator Angie, 309-243-3613, aearles@illinoiscancercare.com

Study Link

« Search Again
WordPress PopUp Plugin